Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

被引：75
|
作者：
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Negrier, S.
Huang, X.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[3] Klin Onkologii Oddzial Chemioterapii, Poznan, Poland
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[5] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[6] Ctr Leon Berard, F-69373 Lyon, France
[7] Pfizer Global Res & Dev, La Jolla, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5024
引用
收藏
页数：1
相关论文
共 50 条
  • [31] TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [33] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
  • [34] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [35] Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by Sunitinib versus first-line Sunitinib Followed by Everolimus in metastatic RCC (mRCC)
    Knox, Jennifer J.
    Barrios, Carlos H.
    Kim, Tae Min
    Cosgriff, Thomas
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray D.
    Beck, J. Thaddeus
    Cheung, Foon-Yiu
    Yadav, Sunil
    Patel, Poulam
    Geoffrois, Lionel
    Schiff, Edward M.
    Niolat, Julie
    Berkowitz, Noah
    Voi, Maurizio
    Motzer, Robert J.
    [J]. BJU INTERNATIONAL, 2015, 116 : 15 - 15
  • [36] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [37] Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).
    Knox, Jennifer J.
    Barrios, Carlos H.
    Kim, Tae Min
    Cosgriff, Thomas
    Srimuninnimit, Vichien
    Pittman, Kenneth B.
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray D.
    Beck, J. Thaddeus
    Cheung, Foon Yiu
    Yadav, Sunil
    Patel, Poulam M.
    Geoffrois, Lionnel
    Schiff, Edward
    Niolat, Julie
    Berkowitz, Noah
    Voi, Maurizio
    Motzer, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
  • [39] Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma
    Rixe, O.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Oudard, S.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [40] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB (SU) VS SORAFENIB (SFN) AND BEVACIZUMAB plus INTERFERON-ALFA (BEV/IFN) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Diaz, S.
    Aller, E. Calvo
    Maroto, P.
    Puente, J.
    Lopez-Brea, M.
    Castellano, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
12345